Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Inhaler Corticosteroid Device Market Size Forecast: How Big Could The Market Get By 2030?
The inhaler corticosteroid device market size has experienced significant expansion in recent years. This market is forecasted to increase from $16.83 billion in 2025 to $17.98 billion in 2026, at a compound annual growth rate (CAGR) of 6.8%. Historically, this growth can be ascribed to a rising prevalence of asthma and COPD, increased awareness concerning inhaler therapies, government programs for respiratory health, developments in metered-dose inhalers, and the expansion of hospital and homecare facilities.
The inhaler corticosteroid device market is anticipated to show significant expansion in the coming years. It is projected to achieve a size of $23.18 billion in 2030, growing at a compound annual growth rate (CAGR) of 6.6%. This expected growth during the forecast period can be attributed to the integration of AI and IoT within inhaler devices, the development of eco-friendly inhalers, the expansion of telehealth services, personalized medication delivery approaches, and increasing demand in emerging markets. Noteworthy trends during this period include the incorporation of smart inhalers, personalized dosage management, monitoring facilitated by telehealth, sustainable and eco-friendly device designs, and advanced aerosol delivery technologies.
Get A Free Sample Report With In-Depth Market Insights:
Inhaler Corticosteroid Device Market Demand Drivers Opening New Revenue Streams
The expansion of the inhaler corticosteroid device market is anticipated to be fueled by the rising occurrence of respiratory conditions. These conditions encompass various ailments impacting the lungs and airways, making it difficult for individuals to breathe properly and efficiently. The increase in respiratory disease prevalence stems from heightened air pollution, leading to exposure to detrimental particles that harm lung tissue and precipitate chronic ailments like asthma and bronchitis. Inhaler corticosteroid devices are utilized to treat respiratory diseases by administering anti-inflammatory medication directly into the lungs, thereby reducing inflammation and enhancing respiration. As an illustration, the Office for Health Improvement and Disparities, a UK-based government department, reported in June 2025 that for the financial year ending 2024, England recorded 854,922 emergency hospital admissions for respiratory diseases. This corresponded to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population, marking a 7% increase compared to the previous year. Consequently, the expanding occurrence of respiratory illnesses is propelling the growth of the inhaler corticosteroid device market.
Inhaler Corticosteroid Device Market Segmentation: How Does The Market Break Down By Category?
The inhaler corticosteroid device market covered in this report is segmented –
1) By Product Type: Metered-Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers
2) By Formulation Type: Fluticasone Propionate, Budesonide, Beclomethasone, Mometasone Furoate
3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Direct Sales, Hospital Pharmacies
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Applications
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Integrated Metered-Dose Inhalers
2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Reservoir Dry Powder Inhalers
3) By Soft Mist Inhalers: Manual Soft Mist Inhalers, Battery-Operated Soft Mist Inhalers
Inhaler Corticosteroid Device Market Trends Powering Strategic Industry Growth
Leading companies in the inhaler corticosteroid device market are concentrating on introducing advanced solutions, such as rescue inhalers that combine albuterol and budesonide, to enhance treatment effectiveness and provide patients with a more convenient, dual-action therapy from a single device. An inhaler blending albuterol and budesonide functions as a dual-action rescue inhaler, delivering both a bronchodilator (albuterol) to rapidly open airways and a corticosteroid (budesonide) to reduce inflammation, thereby offering quick symptom relief and long-term asthma control in one device. For instance, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical industry company, launched AIRSUPRA, the first and only FDA-approved rescue inhaler integrating albuterol and budesonide for adults suffering from asthma. This inhaler is designed for as-needed application to both alleviate acute bronchoconstriction symptoms and decrease airway inflammation, consequently lowering the risk of severe asthma exacerbations. It represents a novel strategy by combining a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a single inhaler, with its approval based on clinical trials demonstrating its superior efficacy over albuterol alone in preventing asthma attacks.
Inhaler Corticosteroid Device Market Leading Players And Competitive Positioning
Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH
View The Full Inhaler Corticosteroid Device Market Report:
Inhaler Corticosteroid Device Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the inhaler corticosteroid device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
